Literature DB >> 32640677

Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines.

Yuka Kuroiwa1, Jun Nakayama1, Chihiro Adachi1, Takafumi Inoue1, Shinya Watanabe2, Kentaro Semba1,3.   

Abstract

HER2 is overexpressed in 25-30% of breast cancers, and approximately 30% of HER2-positive breast cancers metastasize to the brain. Although the incidence of brain metastasis in HER2-positive breast cancer is high, previous studies have been mainly based on cell lines of the triple-negative subtype, and the molecular mechanisms of brain metastasis in HER2-positive breast cancer are unclear. In the present study, we performed intracranial injection using nine HER2-positive breast cancer cell lines to evaluate their proliferative activity in brain tissue. Our results show that UACC-893 and MDA-MB-453 cells rapidly proliferated in the brain parenchyma, while the other seven cell lines moderately or slowly proliferated. Among these nine cell lines, the proliferative activity in brain tissue was not correlated with either the HER2 level or the HER2 phosphorylation status. To extract signature genes associated with brain colonization, we conducted microarray analysis and found that these two cell lines shared 138 gene expression patterns. Moreover, some of these genes were correlated with poor prognosis in HER2-positive breast cancer patients. Our findings might be helpful for further studying brain metastasis in HER2-positive breast cancer.

Entities:  

Keywords:  HER2-positive breast cancer; brain metastasis; in vivo imaging; intracranial injection; microarray

Year:  2020        PMID: 32640677     DOI: 10.3390/cancers12071811

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  5 in total

Review 1.  How to Select Firefly Luciferin Analogues for In Vivo Imaging.

Authors:  Ryohei Saito-Moriya; Jun Nakayama; Genta Kamiya; Nobuo Kitada; Rika Obata; Shojiro A Maki; Hiroshi Aoyama
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

Review 2.  The In Vivo Selection Method in Breast Cancer Metastasis.

Authors:  Jun Nakayama; Yuxuan Han; Yuka Kuroiwa; Kazushi Azuma; Yusuke Yamamoto; Kentaro Semba
Journal:  Int J Mol Sci       Date:  2021-02-14       Impact factor: 5.923

3.  SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma.

Authors:  Tomofumi Yamamoto; Jun Nakayama; Yusuke Yamamoto; Masahiko Kuroda; Yutaka Hattori; Takahiro Ochiya
Journal:  Blood Adv       Date:  2022-04-26

4.  Identification of two cancer stem cell-like populations in triple-negative breast cancer xenografts.

Authors:  Jun Nakayama; Hiroko Matsunaga; Koji Arikawa; Takuya Yoda; Masahito Hosokawa; Haruko Takeyama; Yusuke Yamamoto; Kentaro Semba
Journal:  Dis Model Mech       Date:  2022-06-23       Impact factor: 5.732

5.  High Sensitivity In Vivo Imaging of Cancer Metastasis Using a Near-Infrared Luciferin Analogue seMpai.

Authors:  Jun Nakayama; Ryohei Saito; Yusuke Hayashi; Nobuo Kitada; Shota Tamaki; Yuxuan Han; Kentaro Semba; Shojiro A Maki
Journal:  Int J Mol Sci       Date:  2020-10-24       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.